Pneumocystis jirovecii: Difference between revisions
From IDWiki
Pneumocystis jirovecii
No edit summary |
mNo edit summary |
||
| Line 42: | Line 42: | ||
* Usually instituted if the risk of PJP is greater than 3.5% per year |
* Usually instituted if the risk of PJP is greater than 3.5% per year |
||
{{DISPLAYTITLE:''Pneumocystis jirovecii''}} |
|||
[[Category:Fungi]] |
[[Category:Fungi]] |
||
Revision as of 23:55, 14 August 2019
- Opportunistic fungal infection of the lower respiratory infection
Microbiology
- Previously thought to be Pneumocystis carinii, a close relative that causes disease in rats
Epidemiology
- HIV
- Immune-suppression, e.g. from steroids
Presentation
- Shortness of breath on exertion
Investigations
- CXR
- Typical: bilateral diffuse patchy disease
- Atypical:
- Normal (15%)
- Localized
- Pneumothorax
- Upper lobe, if on pentamidine
- LDH increased
- CBC often normal
Diagnosis
- Induced sputum or brochoalveolar lavage (normal sputum not sensitive enough)
- 6min walk test: will desaturate, even if well-oxygenated at rest
Treatment
- Septra 5-6mg/kg po BID for 3 weeks
- If pO2 <70mmHg or A-a gradient ≥35: prednisone
- Alternative: clindamycin-primaquine or IV pentamidine
- Duration is 21 days (3 weeks)
Prophylaxis
- Usually instituted if the risk of PJP is greater than 3.5% per year
References
- ^ Po-Yi Chen, Chong-Jen Yu, Jung-Yien Chien, Po-Ren Hsueh. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who could not tolerate Trimethoprim/sulfamethoxazole. International Journal of Antimicrobial Agents. 2019. doi:10.1016/j.ijantimicag.2019.10.001.
